ALLMedicine™ Systemic Mastocytosis Center
Research & Reviews 528 results
https://doi.org/10.1186/s13023-023-02661-1
Orphanet Journal of Rare Diseases; Shields AL, Taylor F et. al.
Mar 26th, 2023 - The Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) (©Blueprint Medicines Corporation), a 12-item daily diary that assesses 11 signs and symptoms of indolent systemic mastocytosis (ISM) and smoldering systemic mastocytosis (SSM), ...
https://doi.org/10.1097/DAD.0000000000002404
The American Journal of Dermatopathology; Murphy M, Valentini R et. al.
Mar 21st, 2023 - Mast cell skin disease is rarely described after external beam radiation therapy in patients with breast carcinoma, with only 7 previous reports in the literature. Skin changes typically occur within (but are not limited to) the radiation field. W...
https://clinicaltrials.gov/ct2/show/NCT04910685
Mar 17th, 2023 - This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of BLU-263 + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequ...
https://clinicaltrials.gov/ct2/show/NCT02561988
Mar 17th, 2023 - This is a Phase 1, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (also known as BLU-285), administered orally (PO), in adult...
https://doi.org/10.1038/s41375-023-01871-7
Leukemia Willmann M, Peter B et. al.
Mar 16th, 2023 - Engraftment in NSGSCF mice correlates with the WHO category and prognosis in systemic mastocytosis.|2023|Willmann M,Peter B,Slavnitsch K,Berger D,Witzeneder N,|
Guidelines 1 results
https://doi.org/10.6004/jnccn.2018.0088
Journal of the National Comprehensive Cancer Network : JN... Gotlib J, Gerds AT et. al.
Dec 14th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt...
Drugs 262 results see all →
Clinicaltrials.gov 46 results
https://clinicaltrials.gov/ct2/show/NCT04910685
Mar 17th, 2023 - This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of BLU-263 + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequ...
https://clinicaltrials.gov/ct2/show/NCT02561988
Mar 17th, 2023 - This is a Phase 1, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (also known as BLU-285), administered orally (PO), in adult...
https://clinicaltrials.gov/ct2/show/NCT05186753
Mar 16th, 2023 - This is a multi-part, randomized, double-blind, placebo-controlled Phase 2 clinical study comparing the safety and efficacy of bezuclastinib (CGT9486) plus best supportive care (BSC) with placebo plus BSC in patients with nonadvanced systemic mast...
https://clinicaltrials.gov/ct2/show/NCT04996875
Mar 7th, 2023 - This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast ...
https://clinicaltrials.gov/ct2/show/NCT03770273
Jan 27th, 2023 - Systemic mastocytosis is a disorder caused by clonal mast cell proliferation and release of mast cell mediators including tryptase. As a result, mast cell numbers may increase and affect target organs including the dermis (maculopapular cutaneous ...
News 97 results
https://www.mdedge.com/hematology-oncology/article/260749/mixed-topics/mastocytosis-rare-underdiagnosed-potentially-fatal
Helen Leask, PhD
Jan 24th, 2023 - Systemic mastocytosis is widely underdiagnosed, and many more hematologic oncologists should be looking for it. This call to action was issued late in 2022 by Stanford (Calif.
https://www.mdedge.com/dermatology/article/260439/contact-dermatitis/cutaneous-manifestations-hereditary-alpha-tryptasemia
Allison Kranyak, MD, Marshall Shuler, MD et. al.
Jan 3rd, 2023 - Hereditary alpha tryptasemia (HaT), an autosomal-dominant disorder of tryptase overproduction, was first described in 2014 by Lyons et al. 1 It has been associated with multiple dermatologic, allergic, gastrointestinal (GI) tract, neuropsychiatric,.
https://www.mdedge.com/familymedicine/article/260254/dermatology/incidental-skin-finding
MDedge Family Medicine;
Dec 19th, 2022 - This patient was given a diagnosis of cutaneous mastocytosis. The condition was previously known as urticaria pigmentosa, but in 2016 the World Health Organization reclassified the disease to better suit its pathophysiology as a myeloid cell disor.
https://www.onclive.com/view/avapritinib-meets-primary-and-secondary-end-points-in-pioneer-trial-in-non-advanced-systemic-mastocytosis
Aug 17th, 2022 - Treatment with avapritinib (Ayvakit) led to clinically meaningful and statistically significant improvements in patient-reported symptoms and objective measures of mast cell burden in patients with non-advanced systemic mastocytosis, meeting the p...
https://www.onclive.com/view/bezuclastinib-demonstrates-early-promise-in-advanced-systemic-mastocytosis
Jun 13th, 2022 - Bezuclastinib (formerly PLX 9486) showcased early signs of clinical activity in that it resulted in a meaningful reduction in serum tryptase levels, as well as reductions in mast cell (MC) burden and KIT D816V variant allele frequency (VAF), in ad...
